ArticleEndocrine connections2026
Dynamic testing of cortisol in consecutive patients with suspected adrenal disorders: a comparison of Elecsys Cortisol II and LC-MS/MS.
Article in Endocrine connections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Plasma cortisol cut-off concentrations using the dexamethasone suppression test in patients with adrenal incidentalomas.Frontiers in endocrinology · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Graphical abstract: Abstract: The increased detection of adrenal incidentalomas and drug-induced adrenal insufficiency increases the demand for cortisol testing. While liquid chromatography-tandem mass spectrometry (LC-MS/MS) and dynamic testing remain the gold standard, more expedient tools are needed. We compared the Elecsys Cortisol II immunoassay (ElecsysCort II) with LC-MS/MS during dynamic testing and evaluated the diagnostic performance of baseline cortisol cutoffs (0 min cortisol during a short Synacthen test). The study included 547 overnight dexamethasone suppression tests (44% abnormal), mainly performed in adrenal incidentaloma patients (69%), and 519 Synacthen tests (32% abnormal). ElecsysCort II slightly underestimated cortisol compared with LC-MS/MS with a Passing-Bablok regression of -3.20 (95% CI: -3.66 to -2.83) + 0.96X (95% CI: 0.96-0.97) and a mean relative difference of -8.22% (95% CI: -8.99% to -7.45%) by Bland-Altman, which was within the limits of acceptable bias based on biological variation. Agreement was not affected by glucocorticoid or estradiol intake. Compared with LC-MS/MS, ElecsysCort II demonstrated a specificity of 100%, sensitivity of 84%, positive predictive value of 99%, and negative predictive value of 86% for an abnormal overnight dexamethasone suppression test (480 min cortisol ≥50 nmol/L). For an abnormal Synacthen test (30 min cortisol <420 nmol/L), the measures were 95, 99, 89, and 100%, respectively. A baseline cortisol cutoff >300 nmol/L to rule out and <150 nmol/L to rule in adrenal insufficiency demonstrated a high specificity (>92%) and a positive predictive value (>87%). Our study supports the use of ElecsysCort II in general and baseline cortisol as a screening tool for adrenal insufficiency. The high proportion of abnormal overnight dexamethasone suppression tests among incidentaloma patients warrants further research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.